Y Mabs Therapeutics Stock Analysis
| YMAB Stock | USD 6.19 0.04 0.65% |
Y mAbs Therapeutics is overvalued with Real Value of 5.94 and Hype Value of 6.19. The main objective of Y MAbs stock analysis is to determine its intrinsic value, which is an estimate of what Y mAbs Therapeutics is worth, separate from its market price. There are two main types of Y MAbs' stock analysis: fundamental analysis and technical analysis.
The Y MAbs stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Y MAbs' ongoing operational relationships across important fundamental and technical indicators.
YMAB |
YMAB Stock Analysis Notes
About 12.0% of the company outstanding shares are owned by insiders. The book value of Y MAbs was at this time reported as 2.07. The company has Price/Earnings To Growth (PEG) ratio of 0.04. Y mAbs Therapeutics recorded a loss per share of 0.54. The entity had not issued any dividends in recent years. Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Y-Mabs Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people. For more information please call Michael Rossi at 646 885 8505 or visit https://www.ymabs.com.Y mAbs Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Y MAbs' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Y mAbs Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Y mAbs Therapeutics generated a negative expected return over the last 90 days | |
| Y mAbs Therapeutics has high historical volatility and very poor performance | |
| Y mAbs Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 84.82 M. Net Loss for the year was (21.43 M) with profit before overhead, payroll, taxes, and interest of 75.11 M. | |
| Y mAbs Therapeutics currently holds about 133.66 M in cash with (27.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.06. | |
| Roughly 72.0% of the company outstanding shares are owned by institutional investors |
Y mAbs Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Y MAbs previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
YMAB Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 277.24 M.YMAB Profitablity
The company has Profit Margin (PM) of (0.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.43) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.43.Technical Drivers
As of the 31st of January, Y MAbs maintains the Market Risk Adjusted Performance of (1.11), mean deviation of 2.7, and Standard Deviation of 3.71. Compared to fundamental indicators, the technical analysis model lets you check practical technical drivers of Y mAbs Therapeutics, as well as the relationship between them.Y mAbs Therapeutics Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Y MAbs middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Y mAbs Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Y mAbs Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Y MAbs insiders, such as employees or executives, is commonly permitted as long as it does not rely on Y MAbs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Y MAbs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Y MAbs Outstanding Bonds
Y MAbs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Y mAbs Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most YMAB bonds can be classified according to their maturity, which is the date when Y mAbs Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| XEROX HLDGS P Corp BondUS98421MAB28 | View | |
| XEROX HLDGS P Corp BondUS98421MAA45 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| US98420EAB11 Corp BondUS98420EAB11 | View |
Y MAbs Predictive Daily Indicators
Y MAbs intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Y MAbs stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Y MAbs Forecast Models
Y MAbs' time-series forecasting models are one of many Y MAbs' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Y MAbs' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About YMAB Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Y MAbs prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling YMAB shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Y MAbs. By using and applying YMAB Stock analysis, traders can create a robust methodology for identifying YMAB entry and exit points for their positions.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Y-Mabs Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Y MAbs to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |